Find Pidotimod manufacturers, exporters & distributors on PharmaCompass

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Virtual Booth

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

7 API Suppliers, 2 KDMF, 1 NDC API, 7 Listed Suppliers, $ API Reference Price

7 API Suppliers
2 KDMF
1 NDC API
7 Listed Suppliers
$ API Reference Price

FINISHED DOSAGE FORMULATIONS

8 FDF Dossiers, 6 Europe, 2 Listed Dossiers

8 FDF Dossiers
6 Europe
2 Listed Dossiers

GLOBAL SALES INFORMATION

6 Finished Drug Prices

globalSalesInformation
6 Finished Drug Prices

MARKET PLACE

1 APIs, 2 FDF Dossiers

marketPlace
1 APIs
2 FDF Dossiers

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 295

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 121808-62-6, (r)-3-((s)-5-oxopyrrolidine-2-carbonyl)thiazolidine-4-carboxylic acid, Pidotomod, Pidotimod [inn], Pgt/1a, Pilimod

Molecular Formula

C₉H₁₂N₂O₄S

Molecular Weight

244.27 g/mol

InChI Key

UUTKICFRNVKFRG-WDSKDSINSA-N

FDA UNII

785363R681

Pidotimod is a synthetic dipeptide with immunomodulatory properties.

1 2D Structure

Pidotimod

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(4R)-3-[(2S)-5-oxopyrrolidine-2-carbonyl]-1,3-thiazolidine-4-carboxylic acid

2.1.2 InChI

InChI=1S/C9H12N2O4S/c12-7-2-1-5(10-7)8(13)11-4-16-3-6(11)9(14)15/h5-6H,1-4H2,(H,10,12)(H,14,15)/t5-,6-/m0/s1

2.1.3 InChI Key

UUTKICFRNVKFRG-WDSKDSINSA-N

2.1.4 Canonical SMILES

C1CC(=O)NC1C(=O)N2CSCC2C(=O)O

2.1.5 Isomeric SMILES

C1CC(=O)N[C@@H]1C(=O)N2CSC[C@H]2C(=O)O

2.2 Other Identifiers

2.2.1 UNII

785363R681

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 3-((5-oxo-2-pyrrolidinyl)carbonyl)-4-thiazolidinecarboxylic Acid

2. 3-pyroglutamylthiazolidine-4-carboxylic Acid

3. 3-pyroglutamylthiazolidine-4-carboxylic Acid, (r-(r*,s*))-isomer

4. Adimod

5. Pgt-1a

2.3.2 Depositor-Supplied Synonyms

1. 121808-62-6

2. (r)-3-((s)-5-oxopyrrolidine-2-carbonyl)thiazolidine-4-carboxylic Acid

3. Pidotomod

4. Pidotimod [inn]

5. Pgt/1a

6. Pilimod

7. Nsc-759841

8. (r)-3-((s)-5-oxoprolyl)-4-thiazolidinecarboxylic Acid

9. Pidotimod (inn)

10. (4r)-3-[(2s)-5-oxopyrrolidine-2-carbonyl]-1,3-thiazolidine-4-carboxylic Acid

11. Ncgc00160516-01

12. Polimod

13. (4r)-3-{[(2s)-5-oxopyrrolidin-2-yl]carbonyl}-1,3-thiazolidine-4-carboxylic Acid

14. 785363r681

15. Pidotimodum

16. Pigitil

17. Pidotimodum [inn-latin]

18. 4-thiazolidinecarboxylic Acid, 3-[[(2s)-5-oxo-2-pyrrolidinyl]carbonyl]-, (4r)-

19. Smr000466390

20. Ccris 7271

21. Brn 6636310

22. Onaka

23. Thymodolic Acid

24. Axil

25. Timodolic Acid

26. Pilimod (tn)

27. Pidotimod - Bio-x

28. Unii-785363r681

29. Pidotimod [mi]

30. Pidotimod [mart.]

31. (r-(r*,s*))-3-((5-oxo-2-pyrrolidinyl)carbonyl)-4-thiazolidinecarboxylic Acid

32. Pidotimod [who-dd]

33. (4r)-3-[[(2s)-5-oxo-2-pyrrolidinyl]carbonyl]-4-thiazolidinecarboxylic Acid

34. (r)-3-((s)-(5-oxo-2-pyrrolidinyl)carbonyl)-thiazolidin-4-carbonsaeure [german]

35. Dsstox_cid_26199

36. Dsstox_rid_81430

37. Dsstox_gsid_46199

38. Mls000759528

39. Mls001032108

40. Mls001216453

41. Mls001423953

42. Schembl138407

43. Chembl1488165

44. Dtxsid0046199

45. Pidotimod, >=98% (hplc)

46. Chebi:94618

47. Hms2051c04

48. Hms2231m03

49. Hms3715h06

50. Pharmakon1600-01502322

51. Bcp05222

52. Hy-b0944

53. Zinc3781245

54. Tox21_111865

55. Mfcd00867583

56. Nsc759841

57. S3106

58. (r)-3-((s)-(5-oxo-2-pyrrolidinyl)carbonyl)-thiazolidin-4-carbonsaeure

59. Akos015896354

60. Ac-3493

61. Am90280

62. Ccg-100832

63. Db11364

64. Ks-5229

65. Nc00082

66. Nsc 759841

67. (r)-3-[[(s)-5-oxo-2-pyrrolidinyl]carbonyl]-1,3-thiazolidine-4-carboxylic Acid

68. 4-thiazolidinecarboxylic Acid, 3-((5-oxo-2-pyrrolidinyl)carbonyl)-, (r-(r*,s*))-

69. Ncgc00160516-03

70. Bp164260

71. Cas-121808-62-6

72. P2147

73. Sw197462-2

74. D07261

75. Ab00639966-08

76. Ab00639966_10

77. Ab00639966_11

78. 808p626

79. A804790

80. J-502193

81. Q3902720

82. (4r)-3-[(2s)-5-oxopyrrolidine-2-carbonyl]thiazolidine-4-carboxylic Acid;pidotimod

83. (4r)-3-[[(2s)-5-oxo-2-pyrrolidinyl]carbonyl]thiazolidine-4-carboxylic Acid

84. (4r)-3-[oxo-[(2s)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic Acid

2.4 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	C₉H₁₂N₂O₄S
Molecular Weight	244.27 g/mol
XLogP3	-0.7
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	2
Exact Mass	244.05177804 g/mol
Monoisotopic Mass	244.05177804 g/mol
Topological Polar Surface Area	112 Å²
Heavy Atom Count	16
Formal Charge	0
Complexity	346
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

For use as immunostimulant therapy for treatment of cell-mediated immunosuppression with respiratory or urinary infections.

5 Pharmacology and Biochemistry

5.1 Pharmacology

Pidotimod modulates the immune system to induce an immune response against bacterial or viral pathogens

5.2 MeSH Pharmacological Classification

Adjuvants, Immunologic

Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)

Immunologic Factors

Biologically active substances whose activities affect or play a role in the functioning of the immune system. (See all compounds classified as Immunologic Factors.)

5.3 ATC Code

L - Antineoplastic and immunomodulating agents

L03 - Immunostimulants

L03A - Immunostimulants

L03AX - Other immunostimulants

L03AX05 - Pidotimod

5.4 Absorption, Distribution and Excretion

Absorption

Bioavailability of 45%.

Route of Elimination

95% of intravenous dose is eliminated in the urine as the parent compound.

5.5 Biological Half-Life

Half life of 4 h.

5.6 Mechanism of Action

Pidotimod inhibits tumor necrosis factor (TNF-) induced increases in extracellular signal-related kinase (ERK) phosphorylation. It also increases nuclear factor B (NFB) expression and translocation to the nucleus. It is these to modulatory effects on ERK and NFB signalling which are thought to produce the increase in toll-like receptor expression seen with pidotimod. Pidotimod increase maturation of dendritic cells responsible for presenting antigens to naive Th-cells. It also appears to result in a greater population these cells diiferentiating to Th1 cells which are believed to mediate the immune response to pathogens like bacteria and viruses. Lastly, pidotimod appears to increase antigen-specific antibody titer and cytotoxic response with antigen exposure. The precise mechanism and timeline of events leading to these effects is unknown.

API SUPPLIERS

01

Suanfarma

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPHI Middle east

Booth #1.G23

Suanfarma, at the Core of a Better Life.

Contact Supplier

Spain

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

02

Chynops Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

iPHEX India

Attending

Chynops Pharma is an ideal sourcing partner for high-quality APIs, advanced intermediates, speciality chemicals & excipients.

Contact Supplier

India

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

Product Web Link

03

Jinan Tantu Chemicals

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

Contact Supplier

China

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

04

Wockhardt

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

01

Shandong Jincheng Pharmaceutical Gr...

China

Medlab Asia & Asia Health

Not Confirmed

02

Wockhardt

India

Medlab Asia & Asia Health

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

01

Emeishan Hongsheng Pharmaceutical C...

China

Medlab Asia & Asia Health

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

01

Suanfarma

Spain

CPHI Middle east

Booth #1.G23

Suanfarma, at the Core of a Better Life.

Contact Supplier

Spain

Virtual Booth

Digital Content

Pidotimod

About the Company : Suanfarma founded in 1993, is a B2B life science partner committed to health & innovation by developing, manufacturing, & distributing high-quality APIs for the pharmaceutical indu...

Suanfarma founded in 1993, is a B2B life science partner committed to health & innovation by developing, manufacturing, & distributing high-quality APIs for the pharmaceutical industry innovatively & sustainably. Backed by a robust global network of 12 strategically located local offices, we cater to the needs of over 400 active customers in 70+ countries. At Suanfarma we offer our CDMO capacity for fermentation & chemical synthesis projects, offering a One Stop Shop service with a solid track record, & which allows us to achieve success in the development, scaling, manufacturing, & commercialization of an API, either innovative or generic.

02

Chynops Pharma

India

iPHEX India

Attending

Chynops Pharma is an ideal sourcing partner for high-quality APIs, advanced intermediates, speciality chemicals & excipients.

Contact Supplier

India

Virtual Booth

Digital Content

Pidotimod

About the Company : Chynops Pharma, a company certified with ISO 9001:2015, is situated in Ahmedabad, India. We specialize in exporting, supplying, and trading a wide range of products, including APIs...

Chynops Pharma, a company certified with ISO 9001:2015, is situated in Ahmedabad, India. We specialize in exporting, supplying, and trading a wide range of products, including APIs, Advanced Drug Intermediates, Impurity Standards, Working Standards, KSMs, Industrial Chemicals, Specialty Chemicals, Excipients, Amino Acids, Vitamins, Minerals, Herbal Extracts, Essential Oils, Prebiotics & Probiotics, Veterinary APIs, Solvents, and more from India. Our commitment extends to providing these products to valued customers in both the domestic and global markets.

Product Web Link

03

Jinan Tantu Chemicals

China

Medlab Asia & Asia Health

Not Confirmed

Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

Contact Supplier

China

Virtual Booth

Digital Content

Pidotimod

About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...

Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include customized R&D as well as the production of small molecule pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs) for both international and domestic pharmaceutical firms. Our capabilities span from laboratory-scale kilograms to commercial ton-scale production. Additionally, we are committed to independent research and development, as well as the production and sales of high-end pharmaceutical intermediates and API products.